SCHEMBL4332715

SCHEMBL4332715

CC(C)C[C@H](CO)NC(=O)C(C)(C)C(=O)N[C@@H](CO)CC(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CNR1 P21554 3/20 0.36
TNF P01375 1/20 0.36
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
ADAM17 P78536 1/20 0.36
MME P08473 4/20 0.35
AURKA O14965 1/20 0.35
AURKB Q96GD4 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KISS1R Q969F8 1/20 0.34
CNR2 P34972 2/20 0.33
FPR3 P25089 1/20 0.33
FPR2 P25090 1/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8034340 0.88 TAS1R3 (0.38) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL8034342 0.88 TAS1R3 (0.38) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL2975382 0.82 HDAC4 (0.41) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL2975383 0.82 HDAC4 (0.41) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL5479772 0.82 HDAC4 (0.41) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL4341862 0.79 TAS1R3 (0.42) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL10079223 0.77 MMP1 (0.40) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL25291547 0.77 ALDH1A1 (0.42) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL11073459 0.77 ALDH1A1 (0.52) TAS1R3TAS1R1HDAC4HDAC6CNR1
SCHEMBL3306198 0.77 ALDH1A1 (0.42) TAS1R3TAS1R1HDAC4HDAC6CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612236-B2 Method for producing optically active bisamidoalcohol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-03 US disclosed
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced SUMITOMO CHEMICAL COMPANY, LIMITED 2007-05-03 US disclosed
EP-1698616-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced CCNL2, ARL1, ACSL3 TAS1R3 2130/4885TAS1R1 2720/4885HDAC4 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.